Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth
Blueprint Medicines(BPMC) Seeking Alpha·2025-04-07 17:37文章核心观点 - Blueprint Medicines Corporation是肥大细胞疾病和基因决定癌症疗法的领先开发商，近期扩大了Ayvakit对系统性肥大细胞增多症的影响，其管线还包括BLU - 808 [1]